Suppr超能文献

经上皮两步光治疗性角膜切削术联合角膜交联术(CXL)治疗进行性圆锥角膜:临床结果及术后管理,包括针对美国批准的准分子激光规格设计的改良雅典方案的潜在并发症

Progressive Keratoconus Treatment with Transepithelial Two-Step Phototherapeutic Keratectomy Combined with Corneal Crosslinking (CXL): Clinical Outcomes and Postoperative Management Including Potential Complications of the Modified Athens Protocol Designed for US-Approved Excimer Laser Specifications.

作者信息

Kanellopoulos Anastasios John, Kanellopoulos Alexander J

机构信息

Ophthalmology Department, LaserVision Ambulatory Eye Surgery Unit, 11521 Athens, Greece.

Ophthalmology Department, NYU Grossman Med School, New York, NY 10016, USA.

出版信息

J Clin Med. 2024 Nov 21;13(23):7024. doi: 10.3390/jcm13237024.

Abstract

To report a novel application within the USA of excimer ablation for the normalization of central corneal refractive irregularity, combined with higher fluence CXL in the effective management and visual rehabilitation of progressive keratoconus. 17 consecutive cases with progressive keratoconus were treated with corneal surface excimer laser ablation normalization using topography-guided (Contura) myopic ablation for customized corneal re-shaping with a 6 mm optical zone. The epithelial removal was accounted for by adding a -2.75 diopter correction to this topography-guided normalizing surface ablation followed by a second wavefront-optimized hyperopic excimer treatment of +2.75 diopters also with a 6 mm optical zone. The two sequential excimer ablations applied on the intact epithelium were followed by corneal crosslinking (CXL). Visual acuity, refraction, and keratoconus documentation via keratometry, topography, and pachymetry, as well as endothelial cell density were evaluated over 36 months. Keratoconus stabilized in all cases. The severity and stage of keratoconus determined by the Amsler-Krumeich criteria improved for the OD from an average of 2.2 to 1. The median UDVA showed marked improvement at one-year follow-up (all values in LogMAR), from 0.8 preoperative to 0.3 at 12 months, and was stable through the 3 years at 0.3. The median CDVA increased from 0.5 to 0.1 at 1 year and was stable at 0.1 at 3 years. The average minimal corneal thickness decreased from 466 μm to 396 μm, as recorded the first year postoperatively, and then slightly increased to 405 μm at the 3-year follow-up. We introduce herein the initial clinical data for the use of a novel, off-label therapeutic excimer laser surface ablation application. It was designed to perform both epithelial removal and anterior corneal stroma reshaping and combined with CXL to apply the Athens Protocol CXL with US excimer laser-approved specifications.

摘要

报告在美国将准分子激光消融用于使中央角膜屈光不规则正常化的一种新应用,联合更高能量的角膜交联术(CXL)用于进行性圆锥角膜的有效治疗和视力康复。连续17例进行性圆锥角膜患者接受了角膜表面准分子激光消融正常化治疗,采用地形引导(Contura)近视消融进行定制的角膜重塑,光学区直径为6mm。通过在这种地形引导的正常化表面消融基础上增加-2.75屈光度的矫正来去除上皮,随后进行同样光学区直径为6mm、+2.75屈光度的第二次波前优化远视准分子激光治疗。在完整上皮上进行的这两次连续准分子激光消融之后进行角膜交联(CXL)。在36个月的时间里评估视力、屈光、通过角膜曲率计、地形图和测厚法记录的圆锥角膜情况以及内皮细胞密度。所有病例中圆锥角膜均稳定。根据Amsler-Krumeich标准确定的圆锥角膜严重程度和分期,右眼从平均2.2改善至1。平均未矫正视力(UDVA)在1年随访时显著改善(所有数值采用LogMAR),从术前的0.8提高到12个月时的0.3,并在3年中一直稳定在0.3。平均矫正视力(CDVA)在1年时从0.5提高到0.1,并在3年时稳定在0.1。术后第一年记录的平均最小角膜厚度从466μm降至396μm,然后在3年随访时略微增加至405μm。我们在此介绍一种新型、未获批准的治疗性准分子激光表面消融应用的初始临床数据。其设计目的是同时去除上皮和重塑角膜前基质,并联合CXL以符合美国准分子激光批准规格的雅典方案CXL。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f4ea/11642543/511e8023a963/jcm-13-07024-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验